{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T04:03:48Z","timestamp":1784347428024,"version":"3.55.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.msard.2025.106828","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T17:31:57Z","timestamp":1761931917000},"page":"106828","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Clinical value of plasma C1q, C3, and C4 in NMOSD and MOGAD"],"prefix":"10.1016","volume":"104","author":[{"given":"Yuqing","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zhuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianpeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Congcong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2735-8515","authenticated-orcid":false,"given":"Jie","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.msard.2025.106828_bib0001","doi-asserted-by":"crossref","first-page":"4132","DOI":"10.1007\/s00415-023-11737-8","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): current understanding and challenges","volume":"270","author":"Al-Ani","year":"2023","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2025.106828_bib0002","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.molimm.2018.06.267","article-title":"Blood-brain barrier (BBB) and the complement landscape","volume":"102","author":"Alexander","year":"2018","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.msard.2025.106828_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2025.101944","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): insights into pathogenesis and biomarkers of prognosis","volume":"78","author":"Andersen","year":"2025","journal-title":"Semin. Immunol."},{"issue":"3","key":"10.1016\/j.msard.2025.106828_bib0004","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: international MOGAD Panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.msard.2025.106828_bib0005","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/ana.21802","article-title":"Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica","volume":"66","author":"Bennett","year":"2009","journal-title":"Ann. Neurol."},{"issue":"8","key":"10.1016\/j.msard.2025.106828_bib0006","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1177\/1352458516671203","article-title":"Influence of female sex and fertile age on neuromyelitis optica spectrum disorders","volume":"23","author":"Borisow","year":"2017","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.msard.2025.106828_bib0007","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/WCO.0000000000000766","article-title":"Clinical phenotype, radiological features, and treatment of myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) optic neuritis","volume":"33","author":"Chen","year":"2020","journal-title":"Curr. Opin. Neurol."},{"issue":"21","key":"10.1016\/j.msard.2025.106828_bib0008","doi-asserted-by":"crossref","first-page":"e1858","DOI":"10.1212\/WNL.0000000000005560","article-title":"Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study","volume":"90","author":"Cobo-Calvo","year":"2018","journal-title":"Neurology."},{"issue":"18","key":"10.1016\/j.msard.2025.106828_bib0009","doi-asserted-by":"crossref","first-page":"16516","DOI":"10.1074\/jbc.M111.227298","article-title":"Binding affinity and specificity of neuromyelitis optica autoantibodies to aquaporin-4 M1\/M23 isoforms and orthogonal arrays","volume":"286","author":"Crane","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"11","key":"10.1016\/j.msard.2025.106828_bib0010","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/s41582-020-0400-0","article-title":"Complement in neurological disorders and emerging complement-targeted therapeutics","volume":"16","author":"Dalakas","year":"2020","journal-title":"Nat. Rev. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2025.106828_bib0011","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1212\/NXI.0000000000000012","article-title":"Antibodies to MOG have a demyelination phenotype and affect oligodendrocyte cytoskeleton","volume":"1","author":"Dale","year":"2014","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"3","key":"10.1016\/j.msard.2025.106828_bib0012","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2307\/2531595","article-title":"Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach","volume":"44","author":"DeLong","year":"1988","journal-title":"Biometrics"},{"issue":"6176","key":"10.1016\/j.msard.2025.106828_bib0013","first-page":"1260","article-title":"Complement is activated by IgG hexamers assembled at the cell surface","volume":"343","author":"Diebolder","year":"2014","journal-title":"Science (1979)"},{"key":"10.1016\/j.msard.2025.106828_bib0014","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3389\/fneur.2018.00217","article-title":"MOG-IgG-associated optic neuritis, encephalitis, and myelitis: lessons learned from neuromyelitis optica spectrum disorder","volume":"9","author":"Dos Passos","year":"2018","journal-title":"Front. Neurol."},{"issue":"5","key":"10.1016\/j.msard.2025.106828_bib0015","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s12264-019-00375-8","article-title":"Myelin oligodendrocyte glycoprotein-igg contributes to oligodendrocytopathy in the presence of complement, distinct from astrocytopathy induced by AQP4-IgG","volume":"35","author":"Fang","year":"2019","journal-title":"Neurosci. Bull."},{"issue":"7","key":"10.1016\/j.msard.2025.106828_bib0016","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1177\/1352458516669002","article-title":"Plasma complement biomarkers distinguish multiple sclerosis and neuromyelitis optica spectrum disorder","volume":"23","author":"Hakobyan","year":"2017","journal-title":"Mult. Scler."},{"issue":"24","key":"10.1016\/j.msard.2025.106828_bib0017","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1212\/01.WNL.0000289761.64862.ce","article-title":"Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica","volume":"69","author":"Hinson","year":"2007","journal-title":"Neurology."},{"issue":"5","key":"10.1016\/j.msard.2025.106828_bib0018","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00401-020-02132-y","article-title":"The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody","volume":"139","author":"Hoftberger","year":"2020","journal-title":"Acta Neuropathol."},{"issue":"2","key":"10.1016\/j.msard.2025.106828_bib0019","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.molimm.2014.06.039","article-title":"Complement and blood-brain barrier integrity","volume":"61","author":"Jacob","year":"2014","journal-title":"Mol. Immunol."},{"issue":"1","key":"10.1016\/j.msard.2025.106828_bib0020","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1186\/s12974-016-0719-z","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: brainstem involvement - frequency, presentation and outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J. Neuroinflammation."},{"issue":"12","key":"10.1016\/j.msard.2025.106828_bib0021","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1177\/1352458515622986","article-title":"Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in 'pattern II multiple sclerosis' and brain biopsy findings in a MOG-IgG-positive case","volume":"22","author":"Jarius","year":"2016","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.msard.2025.106828_bib0022","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41572-020-0214-9","article-title":"Wildemann B. Neuromyelitis optica","volume":"6","author":"Jarius","year":"2020","journal-title":"Nat. Rev. Dis. Primers."},{"issue":"1","key":"10.1016\/j.msard.2025.106828_bib0023","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1186\/s12974-020-01824-2","article-title":"Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: results from 163 lumbar punctures in 100 adult patients","volume":"17","author":"Jarius","year":"2020","journal-title":"J. Neuroinflammation."},{"issue":"1\u20132","key":"10.1016\/j.msard.2025.106828_bib0024","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jns.2010.01.002","article-title":"Standardized method for the detection of antibodies to aquaporin-4 based on a highly sensitive immunofluorescence assay employing recombinant target antigen","volume":"291","author":"Jarius","year":"2010","journal-title":"J. Neurol. Sci."},{"issue":"1","key":"10.1016\/j.msard.2025.106828_bib0025","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J. Neuroinflammation."},{"issue":"1","key":"10.1016\/j.msard.2025.106828_bib0026","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12974-016-0717-1","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin","volume":"13","author":"Jarius","year":"2016","journal-title":"J. Neuroinflammation."},{"issue":"7","key":"10.1016\/j.msard.2025.106828_bib0027","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nrneurol.2010.72","article-title":"AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance","volume":"6","author":"Jarius","year":"2010","journal-title":"Nat. Rev. Neurol."},{"issue":"6","key":"10.1016\/j.msard.2025.106828_bib0028","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/bpa.12084","article-title":"Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: a critical review of the literature","volume":"23","author":"Jarius","year":"2013","journal-title":"Brain Pathol."},{"issue":"2","key":"10.1016\/j.msard.2025.106828_bib0029","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/cei.12271","article-title":"Neuromyelitis optica: clinical features, immunopathogenesis and treatment","volume":"176","author":"Jarius","year":"2014","journal-title":"Clin. Exp. Immunol."},{"issue":"9","key":"10.1016\/j.msard.2025.106828_bib0030","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1136\/jnnp-2018-317969","article-title":"CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications","volume":"89","author":"Kaneko","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"2","key":"10.1016\/j.msard.2025.106828_bib0031","first-page":"147","article-title":"Results of a multicenter study of an amoxicillin-clavulanic acid combination in sinusitis in children and adults","volume":"104","author":"Le Clech","year":"1987","journal-title":"Ann. Otolaryngol. Chir. Cervicofac."},{"issue":"9451","key":"10.1016\/j.msard.2025.106828_bib0032","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.msard.2025.106828_bib0033","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200059","article-title":"More Efficient Complement Activation by Anti-Aquaporin-4 Compared With Anti-Myelin Oligodendrocyte Glycoprotein Antibodies","volume":"10","author":"Lerch","year":"2023","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2025.106828_bib0034","article-title":"Plasma complement 3 and complement 4 are promising biomarkers for distinguishing NMOSD from MOGAD and are associated with the blood-brain-barrier disruption in NMOSD","volume":"13","author":"Lin","year":"2022","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.msard.2025.106828_bib0035","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/brain\/awab105","article-title":"Features of MOG required for recognition by patients with MOG antibody-associated disorders","volume":"144","author":"Macrini","year":"2021","journal-title":"Brain"},{"key":"10.1016\/j.msard.2025.106828_bib0036","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/1742-2094-8-184","article-title":"Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders","volume":"8","author":"Mader","year":"2011","journal-title":"J. Neuroinflammation."},{"issue":"12","key":"10.1016\/j.msard.2025.106828_bib0037","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1212\/WNL.0000000000000830","article-title":"Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders","volume":"83","author":"Mao","year":"2014","journal-title":"Neurology."},{"issue":"1","key":"10.1016\/j.msard.2025.106828_bib0038","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1046\/j.1471-4159.1997.69010214.x","article-title":"Demyelinating antibodies to myelin oligodendrocyte glycoprotein and galactocerebroside induce degradation of myelin basic protein in isolated human myelin","volume":"69","author":"Menon","year":"1997","journal-title":"J. Neurochem."},{"key":"10.1016\/j.msard.2025.106828_bib0039","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2021.577699","article-title":"C3 and C4 complement levels in AQP4-IgG-positive NMOSD and in MOGAD","volume":"360","author":"Pache","year":"2021","journal-title":"J. Neuroimmunol."},{"issue":"1","key":"10.1016\/j.msard.2025.106828_bib0040","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/s12974-016-0720-6","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients","volume":"13","author":"Pache","year":"2016","journal-title":"J. Neuroinflammation."},{"issue":"7","key":"10.1016\/j.msard.2025.106828_bib0041","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.msard.2025.106828_bib0042","doi-asserted-by":"crossref","DOI":"10.1172\/JCI140966","article-title":"Endothelial C3a receptor mediates vascular inflammation and blood-brain barrier permeability during aging","volume":"131","author":"Propson","year":"2021","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.msard.2025.106828_bib0043","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.msard.2019.06.035","article-title":"The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders","volume":"35","author":"Qin","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"8","key":"10.1016\/j.msard.2025.106828_bib0044","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1001\/archneurol.2012.249","article-title":"Effects of age and sex on aquaporin-4 autoimmunity","volume":"69","author":"Quek","year":"2012","journal-title":"Arch. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2025.106828_bib0045","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1007\/s13311-022-01206-x","article-title":"Monoclonal antibody therapies beyond complement for NMOSD and MOGAD","volume":"19","author":"Redenbaugh","year":"2022","journal-title":"Neurotherapeutics."},{"issue":"1","key":"10.1016\/j.msard.2025.106828_bib0046","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.1212\/NXI.0000000000000060","article-title":"MOG antibody-associated diseases","volume":"2","author":"Reindl","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"Pt 2","key":"10.1016\/j.msard.2025.106828_bib0047","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/brain\/awp309","article-title":"Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice","volume":"133","author":"Saadoun","year":"2010","journal-title":"Brain"},{"key":"10.1016\/j.msard.2025.106828_bib0048","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/2051-5960-2-35","article-title":"Neuromyelitis optica MOG-IgG causes reversible lesions in mouse brain","volume":"2","author":"Saadoun","year":"2014","journal-title":"Acta Neuropathol. Commun."},{"issue":"4","key":"10.1016\/j.msard.2025.106828_bib0049","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.2214\/AJR.20.24061","article-title":"MOGAD: how it differs from and resembles other neuroinflammatory disorders","volume":"216","author":"Shahriari","year":"2021","journal-title":"AJR Am. J. Roentgenol."},{"issue":"5","key":"10.1016\/j.msard.2025.106828_bib0050","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1172\/JCI122942","article-title":"Membrane assembly of aquaporin-4 autoantibodies regulates classical complement activation in neuromyelitis optica","volume":"129","author":"Soltys","year":"2019","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.msard.2025.106828_bib0051","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/brain\/awaa102","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study","volume":"143","author":"Takai","year":"2020","journal-title":"Brain"},{"key":"10.1016\/j.msard.2025.106828_bib0052","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102005","article-title":"Clinical and immunological differences between MOG associated disease and anti AQP4 antibody-positive neuromyelitis optica spectrum disorders: blood-brain barrier breakdown and peripheral plasmablasts","volume":"41","author":"Tanaka","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"41","key":"10.1016\/j.msard.2025.106828_bib0053","doi-asserted-by":"crossref","first-page":"10948","DOI":"10.1073\/pnas.1707364114","article-title":"Complement-activation fragment C4a mediates effector functions by binding as untethered agonist to protease-activated receptors 1 and 4","volume":"114","author":"Wang","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"2","key":"10.1016\/j.msard.2025.106828_bib0054","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology."},{"issue":"14","key":"10.1016\/j.msard.2025.106828_bib0055","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1177\/1352458519887905","article-title":"Cerebrospinal fluid complement system biomarkers in demyelinating disease","volume":"26","author":"Zelek","year":"2020","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106828_bib0056","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jaut.2014.02.011","article-title":"Longitudinally extensive NMO spinal cord pathology produced by passive transfer of NMO-IgG in mice lacking complement inhibitor CD59","volume":"53","author":"Zhang","year":"2014","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.msard.2025.106828_bib0057","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.3389\/fimmu.2018.01691","article-title":"Functional characterization of alternative and classical pathway C3\/C5 convertase activity and inhibition using purified models","volume":"9","author":"Zwarthoff","year":"2018","journal-title":"Front. Immunol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482500570X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482500570X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T03:36:06Z","timestamp":1784345766000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221103482500570X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":57,"alternative-id":["S221103482500570X"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106828","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical value of plasma C1q, C3, and C4 in NMOSD and MOGAD","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106828","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106828"}}